Duchenne Gene Therapy Company Sarepta Therapeutics Acquires 8% Price Target
earlier today, Sarepta Therapeutics Inc SRPT announced it would file for regulatory approval and seek accelerated FDA approval for SRP-9001 in Duchenne muscular dystrophy (DMD)